Company Profile
Ocular Therapeutix Stock Price, News & Analysis
- Ticker:
- OCUL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.74 USD (+2.82%)
Close
Last updated: August 6, 2026
1.82B USD
Market cap
Why the stock is moving
The latest monitored company update is “Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Sustained Ocular Drug Delivery
Ocular Therapeutix develops bioresorbable hydrogel implants designed to deliver drugs within the eye for extended periods. Its lead franchise seeks to reduce the frequency of anti-VEGF injections for retinal vascular diseases.
AXPAXLI
AXPAXLI is an intravitreal hydrogel implant containing axitinib, a multi-target tyrosine kinase inhibitor with anti-angiogenic activity. The product is designed to sustain disease control in wet age-related macular degeneration and diabetic retinal disease.
Wet AMD Registrational Program
The Phase 3 SOL-1 trial demonstrated superiority in treatment-naïve wet AMD and provides the basis for a planned NDA using Week 52 results, subject to FDA discussions. SOL-R is a separate Phase 3 non-inferiority study, while SOL-X follows patients from both pivotal trials over a longer period.
Diabetic Retinopathy Expansion
HELIOS-3 is an ongoing Phase 3 trial of AXPAXLI in non-proliferative diabetic retinopathy. This study extends the same sustained-delivery technology into an earlier-stage retinal disease population.
Future catalysts
AXPAXLI regulatory and diabetic-retinopathy program updates expected at the June 17, 2026 Investor Day.
Planned AXPAXLI NDA submission for wet AMD based on SOL-1 Week 52 results, subject to FDA alignment.
Topline results from the Phase 3 SOL-R wet AMD trial expected in the first quarter of 2027.
Recent news
- 01
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Ocular Therapeutix
- 02
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Source: Ocular Therapeutix
- 03
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Source: Ocular Therapeutix
- 04
- 05
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Source: Ocular Therapeutix
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ocular Therapeutix (OCUL)?
Ocular Therapeutix (OCUL) most recently closed at 8.74 USD, a +2.82% move versus the previous session.
What is the market cap of Ocular Therapeutix (OCUL)?
Ocular Therapeutix currently has a market capitalization of 1.82B USD on BioPharmSignal.
What does Ocular Therapeutix do?
Sustained Ocular Drug Delivery Ocular Therapeutix develops bioresorbable hydrogel implants designed to deliver drugs within the eye for extended periods. Its lead franchise seeks to reduce the frequency of anti-VEGF injections for retinal vascular diseases. AXPAXLI AXPAXLI is an intravitreal hydrogel implant containing axitinib, a multi-target tyrosine...
On which exchange is OCUL stock listed?
Ocular Therapeutix (OCUL) is associated with NASDAQ, United States, Biopharma.
What is SOL-1?
Planned AXPAXLI NDA submission for wet AMD based on SOL-1 Week 52 results, subject to FDA alignment.
Which conditions is Ocular Therapeutix targeting with SOL-1?
Planned AXPAXLI NDA submission for wet AMD based on SOL-1 Week 52 results, subject to FDA alignment.
How does Ocular Therapeutix describe recent progress with SOL-1?
Planned AXPAXLI NDA submission for wet AMD based on SOL-1 Week 52 results, subject to FDA alignment.
What is SOL-R?
SOL-R is a separate Phase 3 non-inferiority study, while SOL-X follows patients from both pivotal trials over a longer period.